CLEC14A and neoplasm: Our combined findings suggest that this improved antibody may effectively suppress abnormal VEGF‐dependent angiogenesis by CLEC14a‐positive tumor vessels without affecting VEGF signaling in CLEC14a‐negative normal endothelial cells.